On the other hand, DRE testing normally has good specificity, e.g., DRE has been able to determine approximately 25% of clinically significant PCa patients who had been originally reported to display “normal” PSA serum levels [11,12]. This evidence concerns the gene KLK3 and posterior cortical atrophy.